{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:52:45Z","timestamp":1789645965065,"version":"4.0.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nagahama City"},{"name":"Toyooka City"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-38988-5","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T13:15:12Z","timestamp":1770729312000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Autoantibody and disease control stability following mRNA COVID-19 vaccination in rheumatoid arthritis: an observational cohort study"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-1226","authenticated-orcid":false,"given":"Takayuki","family":"Fujii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichiro","family":"Nakabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Morinobu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"38988_CR1","doi-asserted-by":"crossref","unstructured":"Lippi, G., Mattiuzzi, C. & Sanchis-Gomar, F. COVID-19 and obesity: 2025 perspective on epidemiology, pathogenesis, and public health implications. J. Lab. Precis Med. 10, 6 (2025).","DOI":"10.21037\/jlpm-24-57"},{"key":"38988_CR2","doi-asserted-by":"crossref","unstructured":"Ao, D. Y., He, X. M., Liu, J. & Xu, L. Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period. Signal. Transduct. Tar 8(1), 466. (2023).","DOI":"10.1038\/s41392-023-01724-w"},{"issue":"7840","key":"38988_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/d41586-020-03626-1","volume":"589","author":"P Ball","year":"2021","unstructured":"Ball, P. The lightning-fast quest for COVID vaccines - and what it means for other diseases. Nature 589 (7840), 16\u201318 (2021).","journal-title":"Nature"},{"key":"38988_CR4","doi-asserted-by":"crossref","unstructured":"Deng, L. et al. Surveillance and follow up outcomes of myocarditis after mRNA COVID-19 vaccination in Australia. Npj Vaccines. 10(1), 155. (2025).","DOI":"10.1038\/s41541-025-01206-w"},{"key":"38988_CR5","doi-asserted-by":"crossref","unstructured":"Hanson, K. E. et al. Incidence of Guillain-Barre syndrome after COVID-19 vaccination in the vaccine safety datalink. Jama Netw. Open. 5(4), e228879. (2022).","DOI":"10.1001\/jamanetworkopen.2022.8879"},{"key":"38988_CR6","doi-asserted-by":"crossref","unstructured":"Mung, S. M., Goh, T. L., Hughes, M. & Jude, E. B. Inflammatory arthritis associated with COVID-19 vaccination. Cureus J. Med. Sci. 15(3), e35951. (2023).","DOI":"10.7759\/cureus.35951"},{"key":"38988_CR7","doi-asserted-by":"crossref","unstructured":"Sacchi, M. C. et al. The onset of autoantibodies in healthcare workers after mRNA based anti-SARS-CoV-2 vaccines: a single centre prospective follow-up study. Autoimmunity. 56(1), 2229072. (2023).","DOI":"10.1080\/08916934.2023.2229072"},{"issue":"1","key":"38988_CR8","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/s41467-023-36686-8","volume":"14","author":"JR Jaycox","year":"2023","unstructured":"Jaycox, J. R. et al. SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity. Nat. Commun. 14 (1), 1299 (2023).","journal-title":"Nat. Commun."},{"issue":"1","key":"38988_CR9","doi-asserted-by":"publisher","first-page":"6181","DOI":"10.1038\/s41467-024-50656-8","volume":"15","author":"SW Jung","year":"2024","unstructured":"Jung, S. W., Jeon, J. J., Kim, Y. H., Choe, S. J. & Lee, S. Long-term risk of autoimmune diseases after mRNA-based SARS-CoV2 vaccination in a Korean, nationwide, population-based cohort study. Nat. Commun. 15 (1), 6181 (2024).","journal-title":"Nat. Commun."},{"key":"38988_CR10","doi-asserted-by":"publisher","first-page":"102154","DOI":"10.1016\/j.eclinm.2023.102154","volume":"63","author":"K Peng","year":"2023","unstructured":"Peng, K. et al. Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study. EClinicalMedicine 63, 102154 (2023).","journal-title":"EClinicalMedicine"},{"key":"38988_CR11","doi-asserted-by":"publisher","first-page":"1503895","DOI":"10.3389\/fimmu.2024.1503895","volume":"15","author":"A Hoxha","year":"2024","unstructured":"Hoxha, A. et al. COVID-19 vaccine and the risk of flares in inflammatory arthritis: a systematic literature review and meta-analysis. Front. Immunol. 15, 1503895 (2024).","journal-title":"Front. Immunol."},{"issue":"11","key":"38988_CR12","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1136\/ard-2024-225869","volume":"83","author":"B Farisogullari","year":"2024","unstructured":"Farisogullari, B. et al. Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR coronavirus vaccine (COVAX) registry. Ann. Rheum. Dis. 83 (11), 1584\u20131595 (2024).","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"38988_CR13","doi-asserted-by":"publisher","first-page":"103340","DOI":"10.1016\/j.autrev.2023.103340","volume":"22","author":"M Guo","year":"2023","unstructured":"Guo, M., Liu, X., Chen, X. & Li, Q. Insights into new-onset autoimmune diseases after COVID-19 vaccination. Autoimmun. Rev. 22 (7), 103340 (2023).","journal-title":"Autoimmun. Rev."},{"key":"38988_CR14","first-page":"104628","volume":"82","author":"A Rai","year":"2022","unstructured":"Rai, A., Aashish, Priya, Karmani, S., Abbas, W. & Khatri, G. Prevalence of rheumatoid arthritis following COVID-19 vaccine: an autoimmune disorder. Ann. Med. Surg. (Lond). 82, 104628 (2022).","journal-title":"Ann. Med. Surg. (Lond)"},{"issue":"12","key":"38988_CR15","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","volume":"385","author":"N Barda","year":"2021","unstructured":"Barda, N. et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. New. Engl. J. Med. 385 (12), 1078\u20131090 (2021).","journal-title":"New. Engl. J. Med."},{"key":"38988_CR16","doi-asserted-by":"crossref","unstructured":"Wu, Q. H. et al. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. Bmc Med. 19(1),173. (2021).","DOI":"10.1186\/s12916-021-02059-5"},{"issue":"1","key":"38988_CR17","doi-asserted-by":"publisher","first-page":"6514","DOI":"10.1038\/s41467-025-61613-4","volume":"16","author":"Y Pan","year":"2025","unstructured":"Pan, Y. et al. Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study. Nat. Commun. 16 (1), 6514 (2025).","journal-title":"Nat. Commun."},{"key":"38988_CR18","doi-asserted-by":"crossref","unstructured":"Califf, R. M. Consequences and opportunities from poor uptake of COVID vaccinations despite strong evidence. JAMA 333(8), 659-660. (2025).","DOI":"10.1001\/jama.2025.0255"},{"issue":"10416","key":"38988_CR19","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","volume":"402","author":"A Di Matteo","year":"2023","unstructured":"Di Matteo, A., Bathon, J. M. & Emery, P. Rheumatoid arthritis. Lancet 402 (10416), 2019\u20132033 (2023).","journal-title":"Lancet"},{"issue":"4","key":"38988_CR20","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1093\/rheumatology\/keac486","volume":"62","author":"CJT van der Togt","year":"2023","unstructured":"van der Togt, C. J. T. et al. Seroconversion after a third COVID-19 vaccine is affected by rituximab dose but persistence is not in patients with rheumatoid arthritis. Rheumatology 62 (4), 1627\u20131630 (2023).","journal-title":"Rheumatology"},{"key":"38988_CR21","doi-asserted-by":"crossref","unstructured":"Colmegna, I. et al. COVID-19 vaccine in immunosuppressed adults with autoimmune rheumatic diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following moderna Spikevax primary series. RMD Open. 9(4), e003400. (2023).","DOI":"10.1136\/rmdopen-2023-003400"},{"issue":"12","key":"38988_CR22","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/ggi.14506","volume":"22","author":"S Kobayashi","year":"2022","unstructured":"Kobayashi, S., Kusuda, T. & Kubo, K. Influence of COVID-19 vaccination on disease activity of rheumatoid arthritis in older patients. Geriatr. Gerontol. Int. 22 (12), 1052\u20131054 (2022).","journal-title":"Geriatr. Gerontol. Int."},{"key":"38988_CR23","doi-asserted-by":"publisher","first-page":"1314507","DOI":"10.3389\/fimmu.2024.1314507","volume":"15","author":"S Keijzer","year":"2024","unstructured":"Keijzer, S. et al. Longitudinal rheumatoid factor autoantibody responses after SARS-CoV-2 vaccination or infection. Front. Immunol. 15, 1314507 (2024).","journal-title":"Front. Immunol."},{"issue":"6207","key":"38988_CR24","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1126\/science.1259077","volume":"346","author":"Y Ito","year":"2014","unstructured":"Ito, Y. et al. Detection of T cell responses to a ubiquitous cellular protein in autoimmune disease. Science 346 (6207), 363\u2013368 (2014).","journal-title":"Science"},{"key":"38988_CR25","doi-asserted-by":"crossref","unstructured":"Saito, R. et al. Prediction models incorporating second metacarpal cortical index for osteoporosis in rheumatoid arthritis: externally validated machine learning models developed using data from the KURAMA cohort. Int. J. Rheum. Dis. 27(10), e15358. (2024).","DOI":"10.1111\/1756-185X.15358"},{"key":"38988_CR26","doi-asserted-by":"crossref","unstructured":"Fujii, T. et al. Predicting rheumatoid arthritis progression from seronegative undifferentiated arthritis using machine learning: a deep learning model trained on the KURAMA cohort and externally validated with the ANSWER cohort. Arthritis Res. Therapy. 27, 65. (2025).","DOI":"10.1186\/s13075-025-03541-8"},{"issue":"1","key":"38988_CR27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13075-020-02366-x","volume":"22","author":"K Murata","year":"2020","unstructured":"Murata, K. et al. Fluctuation in anti-cyclic citrullinated protein antibody level predicts relapse from remission in rheumatoid arthritis: KURAMA cohort. Arthritis Res. Ther. 22 (1), 268 (2020).","journal-title":"Arthritis Res. Ther."},{"issue":"10","key":"38988_CR28","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.122.059970","volume":"146","author":"M Patone","year":"2022","unstructured":"Patone, M. et al. Risk of myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex. Circulation 146 (10), 743\u2013754 (2022).","journal-title":"Circulation"},{"issue":"1","key":"38988_CR29","doi-asserted-by":"publisher","first-page":"e2352597","DOI":"10.1001\/jamanetworkopen.2023.52597","volume":"7","author":"D Yoon","year":"2024","unstructured":"Yoon, D., Jeon, H. L., Kim, J. H., Lee, H. & Shin, J. Y. Cardiovascular, Neurological, and immunological adverse events and the 23-Valent Pneumococcal polysaccharide vaccine. Jama Netw. Open. 7 (1), e2352597 (2024).","journal-title":"Jama Netw. Open."},{"issue":"2","key":"38988_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1136\/ard-2023-224742","volume":"83","author":"V Konzett","year":"2024","unstructured":"Konzett, V. et al. Definition of rheumatoid arthritis flare based on SDAI and CDAI. Ann. Rheum. Dis. 83 (2), 169\u2013176 (2024).","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"38988_CR31","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jama.2022.9600","volume":"328","author":"N Eldridge","year":"2022","unstructured":"Eldridge, N. et al. Trends in adverse event rates in hospitalized Patients, 2010\u20132019. Jama-J Am. Med. Assoc. 328 (2), 173\u2013183 (2022).","journal-title":"Jama-J Am. Med. Assoc."},{"issue":"1","key":"38988_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13075-023-03251-z","volume":"26","author":"T Fujii","year":"2024","unstructured":"Fujii, T. et al. Management and treatment outcomes of rheumatoid arthritis in the era of biologic and targeted synthetic therapies: evaluation of 10-year data from the KURAMA cohort. Arthritis Res. Ther. 26 (1), 16 (2024).","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"38988_CR33","doi-asserted-by":"publisher","first-page":"e15168","DOI":"10.1111\/1756-185X.15168","volume":"27","author":"T Fujii","year":"2024","unstructured":"Fujii, T. et al. The influence of medial cuneiform inclination on postoperative hallux valgus recurrence in rheumatoid arthritis patients: insights from the KURAMA cohort study. Int. J. Rheum. Dis. 27 (5), e15168 (2024).","journal-title":"Int. J. Rheum. Dis."},{"issue":"521","key":"38988_CR34","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1080\/01621459.2016.1260466","volume":"113","author":"F Li","year":"2018","unstructured":"Li, F., Morgan, K. L. & Zaslavsky, A. M. Balancing covariates via propensity score weighting. J. Am. Stat. Assoc. 113 (521), 390\u2013400 (2018).","journal-title":"J. Am. Stat. Assoc."},{"issue":"23","key":"38988_CR35","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1001\/jama.2020.7819","volume":"323","author":"LE Thomas","year":"2020","unstructured":"Thomas, L. E., Li, F. & Pencina, M. J. Overlap weighting A propensity score method that mimics attributes of a randomized clinical trial. Jama-J Am. Med. Assoc. 323 (23), 2417\u20132418 (2020).","journal-title":"Jama-J Am. Med. Assoc."},{"issue":"5","key":"38988_CR36","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","volume":"11","author":"JM Robins","year":"2000","unstructured":"Robins, J. M., Hern\u00e1n, M. A. & Brumback, B. Marginal structural models and causal inference in epidemiology. Epidemiology 11 (5), 550\u2013560 (2000).","journal-title":"Epidemiology"},{"issue":"5","key":"38988_CR37","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1093\/rheumatology\/keae603","volume":"64","author":"N Nishimura","year":"2025","unstructured":"Nishimura, N. et al. Comparative effects of biological and targeted synthetic DMARDs on incident chronic kidney disease in patients with rheumatoid arthritis. Rheumatology 64 (5), 2395\u20132402 (2025).","journal-title":"Rheumatology"},{"issue":"19","key":"38988_CR38","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1097\/CM9.0000000000002562","volume":"136","author":"Y Geng","year":"2023","unstructured":"Geng, Y. et al. Flare and change in disease activity among patients with stable rheumatoid arthritis following coronavirus disease 2019 vaccination: A prospective Chinese cohort study. Chin. Med. J-Peking. 136 (19), 2324\u20132329 (2023).","journal-title":"Chin. Med. J-Peking"},{"key":"38988_CR39","doi-asserted-by":"crossref","unstructured":"Jernbom, A. F. et al. Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19. Nat. Commun. 15, 8941 (2024).","DOI":"10.1038\/s41467-024-53356-5"},{"key":"38988_CR40","doi-asserted-by":"crossref","unstructured":"Fonseca, D. L. M. et al. Severe COVID-19 patients exhibit elevated levels of autoantibodies targeting Cardiolipin and platelet glycoprotein with age: a systems biology approach. Npj Aging. 9, 21 (2023).","DOI":"10.1038\/s41514-023-00118-0"},{"key":"38988_CR41","doi-asserted-by":"crossref","unstructured":"Galipeau, Y., Cooper, C. & Langlois, M. A. Autoantibodies in COVID-19: implications for disease severity and clinical outcomes. Front. Immunol. 15, 1509289 (2025).","DOI":"10.3389\/fimmu.2024.1509289"},{"key":"38988_CR42","doi-asserted-by":"crossref","unstructured":"Takatani, A. et al. Impact of SARS-CoV-2 mRNA vaccine on arthritis condition in rheumatoid arthritis. Front. Immunol. 14, 1256655 (2023).","DOI":"10.3389\/fimmu.2023.1256655"},{"key":"38988_CR43","doi-asserted-by":"crossref","unstructured":"Buoninfante, A., Andeweg, A., Genov, G. & Cavaleri, M. Myocarditis associated with COVID-19 vaccination. Npj Vaccines 9, 122 (2024).","DOI":"10.1038\/s41541-024-00893-1"},{"issue":"1","key":"38988_CR44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40744-024-00730-w","volume":"12","author":"VDRS Oliveira","year":"2025","unstructured":"Oliveira, V. D. R. S. et al. High-Titer rheumatoid factor is associated with worse clinical outcomes and higher needs for advanced therapies in rheumatoid arthritis under Real-Life conditions. Rheumatol. Ther. 12 (1), 123\u2013136 (2025).","journal-title":"Rheumatol. Ther."},{"key":"38988_CR45","doi-asserted-by":"crossref","unstructured":"Tsuji, H. et al. Time-averaged disease activity fits better joint destruction in rheumatoid arthritis. Sci. Rep. 7(1), 5856 (2017).","DOI":"10.1038\/s41598-017-05581-w"},{"issue":"79","key":"38988_CR46","doi-asserted-by":"publisher","first-page":"eade2798","DOI":"10.1126\/sciimmunol.ade2798","volume":"8","author":"P Irrgang","year":"2023","unstructured":"Irrgang, P. et al. Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci. Immunol. 8 (79), eade2798 (2023).","journal-title":"Sci. Immunol."},{"key":"38988_CR47","doi-asserted-by":"publisher","first-page":"787422","DOI":"10.3389\/fimmu.2021.787422","volume":"12","author":"M Maslinska","year":"2021","unstructured":"Maslinska, M., Dmowska-Chalaba, J. & Jakubaszek, M. The role of IgG4 in autoimmunity and rheumatic diseases. Front. Immunol. 12, 787422 (2021).","journal-title":"Front. Immunol."},{"key":"38988_CR48","doi-asserted-by":"crossref","unstructured":"Sakthiswary, R., Shaharir, S. S. & Wahab, A. A. Frequency and clinical significance of elevated IgG4 in rheumatoid arthritis: A systematic review. Biomedicines. 10(3), 553 (2022).","DOI":"10.3390\/biomedicines10030558"},{"issue":"5","key":"38988_CR49","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/nsb0597-374","volume":"4","author":"AL Corper","year":"1997","unstructured":"Corper, A. L. et al. Structure of human IgM rheumatoid factor fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction. Nat. Struct. Biol. 4 (5), 374\u2013381 (1997).","journal-title":"Nat. Struct. Biol."},{"issue":"18","key":"38988_CR50","doi-asserted-by":"publisher","first-page":"7008","DOI":"10.1074\/jbc.M117.814475","volume":"293","author":"M Shiroishi","year":"2018","unstructured":"Shiroishi, M. et al. Structure-function analyses of a stereotypic rheumatoid factor unravel the structural basis for germline-encoded antibody autoreactivity. J. Biol. Chem. 293 (18), 7008\u20137016 (2018).","journal-title":"J. Biol. Chem."},{"issue":"9","key":"38988_CR51","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1093\/rheumatology\/keh287","volume":"43","author":"N Milosevic-Jovcic","year":"2004","unstructured":"Milosevic-Jovcic, N., Ciric, D., Hajdukovic-Dragojlovic, L. & Mircetic, V. Differences in the relationship of specificity to titre and functional affinity between Circulating Ga- and pan-reactive IgM rheumatoid factors in rheumatoid arthritis. Rheumatol. (Oxford). 43 (9), 1190\u20131193 (2004).","journal-title":"Rheumatol. (Oxford)"},{"issue":"1","key":"38988_CR52","doi-asserted-by":"publisher","first-page":"2259133","DOI":"10.1080\/08916934.2023.2259133","volume":"56","author":"A Franco","year":"2023","unstructured":"Franco, A., Song, J., Chambers, C., Sette, A. & Grifoni, A. SARS-CoV-2 spike-specific regulatory T cells (Treg) expand and develop memory in vaccine recipients suggesting a role for immune regulation in preventing severe symptoms in COVID-19. Autoimmunity 56 (1), 2259133 (2023).","journal-title":"Autoimmunity"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38988-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38988-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38988-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T21:01:57Z","timestamp":1772744517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38988-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["38988"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-38988-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T.F. has received speaker fees from AbbVie GK, Astellas Pharma Inc, Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Co., Taisho Pharmaceutical Co., Ltd., and Janssen Pharmaceutical K.K. K.Murata received research grants and\/or speaker fees from Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Pfizer Inc., Bristol-Myers Squibb, Mitsubishi Tanabe Pharma Corporation, UCB Japan Co., Ltd., Daiichi Sankyo Co., Ltd., and Astellas Pharma Inc. A.O. received research grants and speaker fees from Pfizer Inc., Bristol Myers Squibb, Advantest, Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K. K., Ono Pharmaceutical Co., UCB Japan Co., Mitsubishi Tanabe Pharma Co., Eisai Co. Ltd., AbbVie Inc., Takeda Pharmaceutical Co. Ltd., and Daiichi Sankyo Co. Ltd. K.Murakami received speaking and\/or consulting fees from AbbVie GK, Eisai Co., Ltd., Pfizer Inc., Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corp., Bristol-Myers Squibb, Daiichi Sankyo Co., Ltd., Janssen Pharmaceutical K.K., and Asahi Kasei Pharma Corp. M.T. has received research grants and\/or speaker fees from AbbVie GK, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., Pfizer Inc., Taisho Pharmaceutical Co., Ltd., Tanabe Mitsubishi Pharma Corp., Teijin Pharma, Ltd., UCB Japan Co., Ltd. A.M. received honorarium and research grants from AbbVie G.K., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Eisai Co. Ltd., Pfizer Inc., Bristol-Myers Squibb., Mitsubishi Tanabe Pharma Co., Astellas Pharma Inc., Asahi Kasei Pharma Corp., and Gilead Sciences Japan. S.M. received research grants and\/or speaker fees from Takeda, Eisai, Asahi-Kasei, Astellas, Pfizer, Taisho, Mitsubishi-Tanabe, Daiichi Sankyo Co. Ltd., and Chugai. S.N. has no conflicts of interest to disclose concerning this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8187"}}